A3P Biomedical is a Swedish medical technology company focused on prostate cancer diagnostics. The company's main product, Stockholm3 is a blood-based test that combines protein markers, genetic markers and clinical data to identify the risk of aggressive prostate cancer. The technology enables early detection of severe cases, even in men with low or normal PSA levels. The company is headquartered in Stockholm and collaborates with research institutes and healthcare providers across Europe.
Stockholm3 an innovation in prostate cancer diagnostics
Traditional PSA tests have long been used as a first-line screening method, but have limited reliability. A3P Biomedical has developed Stockholm3 as a more accurate tool for healthcare. The test uses an algorithm that weighs together multiple biomarkers to assess the likelihood of clinically significant cancer.
Results from large studies involving over 90,000 participants show that Stockholm3 can detect up to 89 % more cases of aggressive prostate cancer, while reducing the number of unnecessary examinations by up to 52 %. The studies have been published in scientific journals such as The Lancet Oncology, Journal of Clinical Oncology and European Urology. The research points to both medical and health economic benefits of the test.
Invest in A3P Biomedical
A3P Biomedical is an unlisted company, which means that the share is not traded on any stock exchange. Through Monitor Capital Markets, which is a licensed broker under the supervision of the Swedish Financial Supervisory Authority, investors can be given the opportunity to trade shares in certain unlisted companies. Trading is done by matching buyers and sellers and is not a public offering.
Investing in unlisted companies involves high risk and limited liquidity. It may be difficult to sell the shares and there is no guarantee of future returns. The information on this page does not constitute investment advice but is intended as general information. Anyone considering an investment should carefully read the company's public documents and, if necessary, consult an independent financial adviser.
Are you interested in investing?
Contact us for more information on how to trade and how you can become a shareholder.
Other unlisted companies investors follow
byWiT | Exeger | Xshore | Altris
A selection of companies where we’ve facilitated transactions →
We broker deals in both innovative startups and established corporations. So far, we've completed transactions in more than 130 companies – and we actively track and have insight into over 1,000 companies. Our broad investor network means new opportunities are always on our radar.